Jay Bhimani

Product liability litigation

• A major pharmaceutical company as co-liaison defense counsel in California consolidated litigation involving the claim that the company’s blockbuster H2 receptor antagonist medicine caused patients to develop cancer.
• A manufacturing company in the largest multi-district litigation in history and several bellwether jury trials involving allegations that a product sold to the military is related to hearing loss suffered by servicemen and women.
• A major multinational corporation in numerous jury trials, in which the plaintiffs sought tens of millions of dollars in damages, relating to the company’s consumer talcum powder products.

Qui tam and pharmaceutical litigation

• A prominent healthcare foundation in a qui tam action alleging violations of the federal Anti-Kickback Statute. Obtained summary judgment on all pending claims and unanimous affirmance in the 11th Circuit.
  
• A supplier of over-the-counter generic pharmaceutical products in a contract dispute with a counterparty, including during expedited proceedings relating to a requested injunction.
  

• A prominent hedge fund and its principal in a class action in which the named plaintiffs (two pension funds) asserted SEC Rule 14e-3 causes of action relating to stock and options transactions made in advance of the announcement of a proposed merger.
• The US broker/dealer arm of one of Europe’s largest banking groups and its affiliates in multiple actions brought by the National Credit Union Administration Board on behalf of four liquidated corporate credit unions relating to the sale of billions of dollars of residential mortgage-backed securities.
  
• A prominent U.S. investment bank and its affiliates in litigation commenced by CUNA Mutual, an affiliated group of insurance companies, seeking to rescind the purchase of approximately US$72 million of residential mortgage-backed securities.
  
• An activist capital management firm in federal securities litigation brought by Botox-maker Allergan, Inc. relating to an unsolicited merger proposal of over US$50 billion.
  
• A publicly-traded Maryland real estate investment trust in litigation concerning a hedge fund-shareholder's proposal to nominate additional directors to the client's Board.
  
• Six financial institutions in Taiwan with investments in PEM Group, in a suit against HSBC for fraud and aiding and abetting fraud by PEM Group. Defeated HSBC's motions to dismiss and change venue to the British Virgin Islands, at which point the case settled on very favorable terms.
  
• The founder and former CEO of a major California mortgage lender in a bankruptcy action for fraudulent conveyance and breach of fiduciary duties related to the failure of the lender. Obtained a favorable settlement on behalf of the client.

• A commercial lender in a fraud and breach of contract action arising out of prospective loan transaction with crowdfunded borrower.
  
• A movie studio in antitrust litigation filed by distributor alleging a vertical conspiracy to boycott.
  
• A casino and resort company in litigation brought by a creditor alleging actual and constructive fraudulent conveyances.
  
• A corporation in connection with a Foreign Corrupt Practices Act investigation.
  
• An auction company and its directors and officers in breach of contract litigation alleging alter ego claims.
  
• An overseas development and manufacturing company in breach of contract and fraud action against warehousing and logistics provider that failed to provide promised services.
  

• Due Process in Action: Plaintiff’s Leadership Roles in JCCPs — Daily Journal (November 29, 2024)
• Drafting and Exchanging Exhibit Lists for a Federal Civil Trial — Thomson Reuters (Summer 2022)
• Presenting and Handling Exhibits in a Civil Trial — Thomson Reuters (December 2021/January 2022)